First and foremost, the company, Contract Research, Development, and Manufacturing Organization submitted DRHP to the SEBI on 2nd January and received approval on 3rd April.
This IPO is entirely OFS of ₹3,395 crores by promoters and investors, so no new shares are going to be allocated in this IPO, and the proceeds will go to promoters. However, a listing would assist the company to grow and enhance brand visibility.
Sai Life Science, Suven Life Science, Divi’s Laboratories, and Syngene International are the peer groups of this company.
The Book Running Lead Managers for the offer are JM Financial, Citigroup Global Markets India, JP Morgan India, and Nomura Financial Advisory and Securities (India).
Moreover, Kfin Tech will handle administrative and record-keeping tasks.
This IPO is going to be listed on the NSE(National and Securities Stock Exchange) and BSE exchanges.
About Anthem Biosciences
Anthem Biosciences was founded in 2006 by Ajay Bhardwaj and is involved in a contract research, development, and manufacturing organization (CRDMO). This is based in Bengaluru. Furthermore, the company started by providing early-stage drug discovery services.
Over time, this has become one of the best in cutting-edge areas such as RNA interference, antibody-drug conjugates, peptides, lipids, and oligonucleotides.
From 2006, it has expanded two manufacturing facilities in Karnataka and in 2024 facilities have a combined capacity for a custom synthesis of 270 kiloliters (kL) annually, and a fermentation capacity of 142 kL per year. Financially, this company’s revenue portion is robust as it has increased 30% (1,419 crores)in 2024 from 2023 to ₹1,056 crores. However, PAT(Profit After Tax) was 365 crores in FY24, reduced from ₹ 385 crores in FY 2023.
Anthem Biosciences IPO Prospectus:
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | To be Updated Soon |
Anthem Biosciences Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax |
| 2022 | ₹1280.24 | ₹734.10 | ₹405.54 |
| 2023 | ₹1133.99 | ₹698.50 | ₹385.19 |
| 2024 | ₹1483.07 | ₹1005.75 | ₹367.31 |
| September 2024 | ₹910.85 | ₹593.34 | ₹244.31 |
Anthem Biosciences IPO Valuation – FY2024
Anthem Biosciences IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| Earning Per Share (EPS): | ₹6.48 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 20.03% |
| Net Asset Value (NAV): | ₹34.43 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Syngene International Limited | 12.71 | 67.23 | 12.95% | 105.91 | 3,579.20 Cr. |
| Sai Life Sciences Limited | 4.57 | 168.94 | 8.89% | 53.83 | 1,494.27 Cr. |
| Suven Life Sciences Limited | 11.80 | 105.67 | 15.86% | 80.56 | 1,113.26 Cr. |
| Divi’s Laboratories Limited | 60.27 | 97.03 | 12.15% | 511.21 | 8,184.00 Cr. |
Objects of the Issue
- To be updated soon
IPO Lead Managers aka Merchant Bankers
- JM Financial Limited
- Citigroup Global Markets India Private Limited
- J.P. Morgan India Private Limited
- Nomura Financial Advisory and Securities (India) Private Limited
